2nd Meeting of European Task Group for Endocrine Cancers - ESE Special Interest Group - Programme

Meeting of the European Task Group
for Endocrine Cancers - ESE Special Interest Group
“Endocrine cancers and endocrine oncology”

May 28th, 2016, Munich, Germany

 

Holiday Inn Munich – City Centre, Hochstrasse 3, D-81669 Munich

 

08:30 – 08:45 Welcome and coffee

08:45 – 09:00 Information on the activity and goals of ETEC

Barbara Jarząb, Poland

 

09:00 – 10:50 SESSION 1: Genetic heterogeneity of endocrine cancers

Chairs: Felix Beuschlein, Christine Spitzweg

 

09:00 – 09:45 Heterogeneity of thyroid cancer

James Fagin, USA

09:45 – 10:00 Discussion

10:00 – 10:30 Heterogeneity of neuroendocrine tumors

Justo Castagno, Spain

10:30 – 10:35 Discussion

10:35 – 10:50 Coffee break

 

10:50 – 12:35 SESSION 2: Molecular studies in endocrine cancer and their impact
for personalized therapy

Chairs: Martin Fassnacht, Barbara Jarząb

 

10:50 – 11:20 Advances in molecular understanding of thyroid cancer

Clara Alvarez, Santiago de Compostela, Spain

11:25 – 11:55 Molecular understanding of adrenal cancer in the clinical context of the disease

Guillaume Assie, France

12:00 – 12:30 Genetic testing beyond diagnosis in pheochromocytoma
and paraganglioma. The path
to discovery of new genes, biomarkers and targets

Mercedes Robledo, Madrid, Spain

after each talk 5 minutes for discussion is provided

 

12:35 – 13:30 Lunch break

 

13:30 – 15:45 SESSION 3: Clinical issues in endocrine cancer

Chairs: Lionel Groussin, Anna Maria Colao

 

13:30 – 14:00 The necessity of multidisciplinary approaches for the research and treatment of NETs – a surgeons perspective

Massimo Falconi, Milan, Italy

14:05 – 14:35 Towards a new understanding and classification of aggressive pituitary tumors. Would it influence their management and treatment?

Gerald Raverot, Lyon, France

14:40 – 15:10 FIRST-MAPPP and beyond – perspectives in clinical studies for malignant pheochromocytoma

Eric Baudin, France

15:15 – 15:45 New ATA recommendation for differentiated thyroid cancer management from the point of view of European endocrinologist.

Furio Pacini, Siena, Italy

after each talk 5 minutes for discussion is provided

 

15:50 – 16:00 Summary and conclusions